In News

To the Organ Transplantation Community,

In keeping with the Bridge to Life mission and philosophy of offering premier organ transplantation products with a strong focus on product quality, innovation and accessibility in partnership with leading Transplant Centers and Organ Procurement Organizations (OPO) globally, I am excited to introduce here a periodic blog where I will update our community on Bridge to Life research, clinical and developmental progress, events and other items of potential interest.

Since I joined Bridge to Life as Chief Executive Officer in October 2022, we have made significant progress in advancing our mission of saving lives by developing preservation solutions and technologies while providing the highest quality of service to organ procurement organizations and transplant centers. The leadership team at Bridge to Life recognizes that partnership with the global clinical innovators in donation and transplant is at the core of success. Our goal is nothing short of reimagining the future of organ transport and preservation.

In early 2023, Bridge to Life announced the expansion our executive leadership team by appointing Bob Beechey as Chief Financial Officer and Blago Herrera as Vice President of Operations. What this means for you, our valued customers and partners, is a more efficient operation and that allows us to focus on YOUR needs.

We were proud to have shared results of the interim analysis of our Bridge to HOPE clinical trial, demonstrating promising findings with Hypothermic Oxygenated Perfusion. The Bridge to HOPE Trial is being conducted under U.S. Food and Drug Administration (FDA) approved investigational device exemption (IDE) to evaluate the clinical safety and efficacy of static cold storage (SCS), the current standard for ex-vivo organ preservation, compared to SCS followed by hypothermic oxygenated perfusion (HOPE) with the VitaSmart™ Liver Machine Perfusion System. The interim analysis of this multicenter, randomized, controlled liver clinical trial was presented at the 2023 American Transplant Congress (ATC).

Results from the planned interim analysis of the first 170 enrolled patients undergoing liver transplantation showed a lower rate of early allograft dysfunction (EAD) in the HOPE arm (19%) compared to the SCS arm (39%), a statistically superior finding for the trial’s primary endpoint. These benefits were observed without device-related serious adverse events.

In other Bridge to Life news, we were pleased to be able to bring EasiSlush™ back to market, following a production hiatus.  We continue to make significant investments in our Quality Management System and supply chain and have hired highly experienced senior managers, engineers and manufacturing talent over the past year.

And what lies ahead? 2024 is already proving to be an event-filled year.

Bridge to Life will have a significant presence at major global organ transplantation conferences in 2024, including, among others, The European Society of Organ Transplantation (ELITA Summit 2024, April 18-24 in Madrid), International Liver Transplant Society (ILTS 2024, May 1-4 in Houston); American Transplant Congress (ATC 2024, June 1-5 in Philadelphia); and the International Congress of The Transplantation Society (TTS 2024, September 22-25 in Istanbul).

You can expect further updates from me as the year progresses and Bridge to Life has more news to share with you, the organ transplantation community, whom we are dedicated to serve and support.

Also, I welcome hearing from you regarding what would be valuable in these blog updates moving forward. You can reach out to me at BTLBlog@b2ll.com.

Don Webber
Chief Executive Officer
Bridge to Life Ltd.